Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pamlab, L.L.C.
With
Baylor Health Care System
Norman Regional Health System
Five Oaks Medical Group
Age
21–39
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Pregnant females, age 21-39, who received either Neevo®/NeevoDHA® or another standard prenatal vitamin (Prenatal vitamins must contain ≤1 mg folic acid, 27-35mg iron, and ≤12mcg vitamin B12).
Clinical diagnosis of pregnancy must have been made at ≤12 weeks of Pregnancy, and delivery must have occurred on or after January 1, 2008 and on or before March 31, 2010
Subjects must have been compliant in taking Neevo®/NeevoDHA® or other prenatal vitamin
You may not be if
Subjects should not have taken Prenate®, Prenate®DHA, or Prenate® Elite, which are L-methylfolate-containing prenatal vitamins.
The following supplements within 2 months of diagnosis of pregnancy: B12 injection; \> 35mg Iron; \> 1.2 mg of folate; or a L-methylfolate product that is not a prenatal vitamin such as Life Extension methylfolate, Prothera methylfolate, Thorne 5-MTHF, Metanx®, Deplin®, Cerefolin®, or CerefolinNAC®
History of leukemia or any anemia other than iron deficiency anemia or;
Taking any iron supplement (in addition to the prenatal vitamin) prior to Week 22
Clareo Health | A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy
